# Effect of Serum LDL Cholesterol Concentration on Pancreatic Insulin Secretion

> **NCT04314167** · NA · TERMINATED · sponsor: **University Hospital Tuebingen** · enrollment: 9 (actual)

## Conditions studied

- Hypercholesterolemia
- Insulin Resistance
- Insulin Secretion

## Interventions

- **DRUG:** Lowering cholesterol concentrations by PCSK-9 inhibitor

## Key facts

- **NCT ID:** NCT04314167
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-28
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** poor recruitment
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04314167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04314167, "Effect of Serum LDL Cholesterol Concentration on Pancreatic Insulin Secretion". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04314167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*